Benjamin Solomon is a Medical Oncologist at the Peter MacCallum Cancer Centre in Melbourne, Australia. He serves as the Group Leader of the Molecular Therapeutics and Biomarkers Laboratory, focusing on translational lung cancer research. He has an interest in translational lung cancer research and completed a PhD investigating the mechanisms by which EGFR inhibition enhances the effects of radiation, as well as subsequent postdoctoral studies at the University of Colorado investigating novel predictive markers for therapy with EGFR inhibitors. His work has been pivotal in the development of novel therapies targeting ALK, ROS1, NTRK, BRAF, cMET, RET and KRAS. These efforts have led to the approval of several targeted therapies, including crizotinib, ceritinib, lorlatinib, repotrectinib and selpercatinib, changing treatment outcomes for patients with lung cancer. Professor Solomon has over 200 peer-reviewed publications and has been recognised as a Clarivate Highly Cited Researcher (2019, 2020, 2021, 2022).